Literature DB >> 32613390

Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study.

Khalaf Kridin1, Giovanni Damiani2,3, Arnon D Cohen4.   

Abstract

BACKGROUND: The association between pyoderma gangrenosum (PG) and rheumatoid arthritis (RA) was not investigated in the setting of controlled studies. The risk of PG among patients with RA is not established.
OBJECTIVE: The study aims to evaluate the magnitude of the association between RA and the subsequent development of PG. Additionally, we aimed to characterize patients with RA-associated PG relative to other patients with PG.
METHODS: A population-based case-control study was conducted comparing PG patients (n = 302) with age-, sex-, and ethnicity-matched control subjects (n = 1497) with respect to the presence of RA. Logistic regression models were utilized for univariate and multivariate analyses.
RESULTS: The prevalence of RA was greater in patients with PG than in control subjects (4.7% vs. 1.5%, respectively; P < 0.001). More than threefold increase in the odds of PG with RA (OR, 3.29; 95% CI, 1.66-6.50) was noted. This association retained its statistical significance following a sensitivity analysis excluding RA cases diagnosed up to 2 years prior to PG (OR, 2.72; 95% CI, 1.25-5.91) and after adjusting for confounding factors (adjusted OR, 2.80; 95% CI, 1.23-5.86). RA preceded the diagnosis of PG in the majority of patients by a mean (SD) latency of 9.2 (7.4) years. Patients with RA-associated PG were older relative to the remaining patients with PG (62.2 [15.0] vs. 53.4 [20.9] years, respectively; P = 0.006).
CONCLUSIONS: RA increases the odds of developing PG by more than threefold. Physicians managing patients with RA should be aware of this increased burden. Patients with RA may be advised to avoid additional precipitating factors of PG. Key Points • The odds of developing PG are increased by more than threefold in patients with RA. • PG followed the diagnosis of RA in the majority of patients with these coexistent conditions by an average latency of 9.2 years. • Patients with RA-associated were older relative to other patients with PG at the onset of PG.

Entities:  

Keywords:  Case-control study; Pyoderma gangrenosum; Rheumatoid arthritis

Mesh:

Year:  2020        PMID: 32613390     DOI: 10.1007/s10067-020-05253-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum.

Authors:  A G Ortega-Loayza; W H Nugent; O M Lucero; S L Washington; J R Nunley; S W Walsh
Journal:  Br J Dermatol       Date:  2017-12-05       Impact factor: 9.302

2.  Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking.

Authors:  Henry Roberts; Shesh N Rai; Jianmin Pan; J Michael Rao; Robert C Keskey; Ziad Kanaan; Ethan P Short; Edward Mottern; Susan Galandiuk
Journal:  Digestion       Date:  2014-10-01       Impact factor: 3.216

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  Rheumatoid arthritis: a review of the cutaneous manifestations.

Authors:  Anousheh Sayah; Joseph C English
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

Review 5.  Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis.

Authors:  Khalaf Kridin; Arnon D Cohen; Kyle T Amber
Journal:  Am J Clin Dermatol       Date:  2018-08       Impact factor: 7.403

Review 6.  Pathophysiology of pyoderma gangrenosum (PG): an updated review.

Authors:  Sara F Braswell; Tassia C Kostopoulos; Alex G Ortega-Loayza
Journal:  J Am Acad Dermatol       Date:  2015-08-05       Impact factor: 11.527

7.  Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features.

Authors:  D Vidal; L Puig; M Gilaberte; A Alomar
Journal:  J Dermatolog Treat       Date:  2004-06       Impact factor: 3.359

8.  Pyoderma gangrenosum: a review of 86 patients.

Authors:  F C Powell; A L Schroeter; W P Su; H O Perry
Journal:  Q J Med       Date:  1985-05

9.  Pyoderma Gangrenosum: A Report of 27 Patients.

Authors:  Esra Adışen; Funda Erduran; Mehmet Ali Gürer
Journal:  Int J Low Extrem Wounds       Date:  2016-03-23       Impact factor: 2.057

Review 10.  Smoking and rheumatoid arthritis.

Authors:  Kathleen Chang; So Min Yang; Seong Heon Kim; Kyoung Hee Han; Se Jin Park; Jae Il Shin
Journal:  Int J Mol Sci       Date:  2014-12-03       Impact factor: 5.923

View more
  3 in total

1.  Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor.

Authors:  Morton Scheinberg; Luis Antônio Machado; Luiz Guilherme M Castro; Sineida Berbert Ferreira; Nilceo Michalany
Journal:  J Transl Autoimmun       Date:  2021-04-15

2.  Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.

Authors:  Erika Sawka; Allison Zhou; Emile Latour; Marcia Friedman; Alex G Ortega-Loayza
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 3.650

3.  Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association.

Authors:  Khalaf Kridin; Eran Shavit; Giovanni Damiani; Arnon D Cohen
Journal:  Immunol Res       Date:  2021-08-19       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.